PCA3 Urine Test: Prostate Cancer Risk, PSA Follow-Up, Repeat Biopsy, and Meaning

The PCA3 urine test measures prostate cancer antigen 3 RNA, a prostate-associated long noncoding RNA that is often produced at much higher levels in prostate cancer tissue than in benign prostate tissue. The best-known clinical version was the PROGENSA PCA3 Assay, which used urine collected after a digital rectal examination and reported a PCA3 score based on PCA3 RNA relative to PSA RNA. It was designed mainly to help decide whether men age 50 or older with a previous negative prostate biopsy should undergo another biopsy. A higher score increased the likelihood of a positive repeat biopsy, while a lower score reduced it, but the test never diagnosed cancer by itself. The FDA-approved PROGENSA assay used a cutoff of 25; its U.S. PMA was withdrawn in 2023, so current availability is different from its historical use. PCA3 remains important in prostate biomarker research and in some multi-marker approaches, but modern biopsy decisions increasingly integrate PSA, MRI, newer biomarkers, prior pathology, and individual risk.

• PCA3 measures prostate cancer-associated RNA in urine, usually after a digital rectal examination designed to release prostate material into the urine.
• The historical PROGENSA PCA3 score equals PCA3 RNA divided by PSA RNA, multiplied by 1,000.
• For the FDA-approved PROGENSA assay, a score below 25 was interpreted as negative and a score of 25 or higher as positive, with values near the cutoff requiring caution.
• A high PCA3 score increases the likelihood of cancer on biopsy but does not prove cancer, grade it, or stage it.
• The PROGENSA PCA3 PMA was withdrawn in the United States in April 2023, so patients should confirm which current assay, if any, is actually being offered.

Table of Contents

• What the PCA3 Urine Test Measures
• How PCA3 Urine Is Collected and Scored
• What Low, High, and Borderline PCA3 Scores Mean
• PCA3 After a High PSA or Negative Biopsy
• Accuracy and Important Limitations
• Where PCA3 Fits in Prostate Testing Today
• Next Steps After a PCA3 Result

What the PCA3 Urine Test Measures

PCA3 stands for prostate cancer antigen 3. Despite the name, PCA3 is not a protein antigen measured like PSA. It is a long noncoding RNA, meaning it is an RNA molecule that does not serve as a template for making a conventional protein. PCA3 is expressed at very low levels in most normal tissues and is markedly overexpressed in many prostate cancers.

That biology made PCA3 attractive as a more prostate-cancer-specific signal than serum PSA. The PSA blood test is produced by normal as well as malignant prostate cells. Benign prostate enlargement, inflammation, age-related changes, and procedures can raise PSA, so an elevated PSA often creates uncertainty rather than establishing a diagnosis.

PCA3 was developed to answer a narrower question: How likely is a prostate biopsy to be positive in a man who already has enough concern to be considering biopsy? It became especially associated with repeat-biopsy decisions after an earlier biopsy did not find cancer.

The assay does not identify a tumor’s location, volume, Gleason pattern, Grade Group, or stage. It also does not measure whether prostate cancer has spread. Those questions require imaging, tissue pathology, and other clinical evaluation.

PCA3 should also not be confused with newer urine tests that may include PCA3 as one part of a multi-gene algorithm. For example, the ExoDx Prostate test measures PCA3 together with ERG and SPDEF in urinary exosomes and does not require a preceding digital rectal examination. A PCA3-containing test is not automatically the same as the historical PROGENSA PCA3 assay.

How PCA3 Urine Is Collected and Scored

The historical PROGENSA PCA3 protocol required a digital rectal examination (DRE) before urine collection. The clinician applied pressure to the prostate, typically with several firm strokes to each lobe, to release prostate cells and RNA into the urethra. The patient then provided the first portion of urine, which contained the prostate-derived material needed for molecular testing.

This pre-DRE collection requirement is one reason PCA3 differs from some newer non-DRE urine biomarkers. If a urine sample was collected without the required prostate manipulation for an assay designed around post-DRE urine, the result may not be valid.

The PROGENSA assay measured two RNA signals:

• PCA3 RNA, the cancer-associated target; and
• PSA RNA, used to indicate the amount of prostate-derived material in the specimen and normalize the PCA3 signal.

The score was calculated as:

PCA3 score = (PCA3 RNA copies ÷ PSA RNA copies) × 1,000

Using PSA RNA in the denominator helped account for how much prostate material entered the urine. A sample with too little PSA RNA could be considered insufficient because there was not enough prostate-derived material for reliable interpretation.

No special dietary preparation is central to PCA3 testing. The important preparation is following the correct specimen-collection protocol. Patients should tell the clinician about current urinary infection, recent prostate or urinary procedures, and any reason the examination or urine collection might need to be delayed.

The exact protocol depends on the assay being used. Because the original PROGENSA product is no longer an active U.S. PMA device, someone offered “PCA3 testing” today should ask for the exact test name, laboratory, collection instructions, and interpretation system rather than assuming that the historical 25 cutoff applies.

What Low, High, and Borderline PCA3 Scores Mean

For the FDA-approved PROGENSA PCA3 Assay, the official cutoff was 25.

PCA3 score	Historical interpretation	General meaning
Below 25	Negative	Associated with a decreased likelihood of a positive repeat biopsy
25 or higher	Positive	Associated with a higher likelihood of cancer on repeat biopsy
About 18–31	Near-cutoff zone	Official labeling advised caution because normal assay variation could change classification on repeat testing

The cutoff was not a biologic wall between cancer and no cancer. In a prospective multicenter repeat-biopsy study of 466 men, a cutoff of 25 had about 77.5% sensitivity, 57.1% specificity, a 90% negative predictive value, and a 33.6% positive predictive value for the study population. Men with scores below 25 were substantially more likely to have a negative repeat biopsy than men with scores of 25 or higher.

These numbers illustrate the correct interpretation. A low result reduced risk but did not eliminate cancer. A high result raised risk but produced many false positives. Predictive values also change when the underlying prevalence of prostate cancer changes, so the study percentages should not be treated as universal personal probabilities.

Older research sometimes used different thresholds, particularly 35, which is why patients may encounter several “normal” PCA3 cutoffs online. Those thresholds came from different study designs and clinical aims. If reviewing a historical PROGENSA report, the FDA-approved 25 cutoff is the appropriate starting point. If reviewing another PCA3-based assay, use that assay’s validated reporting system.

A PCA3 score should never be used to infer Grade Group. Evidence linking PCA3 level to aggressive pathologic features has been inconsistent, which is another reason the test was primarily a biopsy-decision aid rather than a prognostic or staging marker.

PCA3 After a High PSA or Negative Biopsy

PCA3 became clinically relevant because PSA often remains elevated after a negative biopsy. A negative biopsy reduces the immediate likelihood of cancer but does not make future risk zero. Sampling can miss a tumor, PSA may continue to rise, or a new lesion may develop later.

Historically, PROGENSA PCA3 was indicated as an aid in deciding whether repeat biopsy was necessary in men age 50 or older who had one or more previous negative prostate biopsies and for whom another biopsy was being considered. It was not intended to replace PSA screening or to serve as a stand-alone initial diagnostic test.

The logic was straightforward. If repeat biopsy already seemed clearly necessary because of a very suspicious examination or other findings, PCA3 added little. If repeat biopsy seemed clearly unnecessary, testing also added little. Its best use was in the uncertain middle, where a lower or higher molecular risk signal might change the decision.

Today, repeat-biopsy evaluation has evolved. A clinician may look at:

• repeat and trend-based PSA results;
• prostate volume and PSA density;
• percent free PSA or other PSA derivatives;
• prior biopsy quality and pathology;
• multiparametric prostate MRI and PI-RADS score;
• family history and inherited cancer-risk variants; and
• blood or urine biomarker tests when the result would affect management.

A percent free PSA result, the Prostate Health Index, or the 4Kscore may be considered in some settings. These tests measure different signals and should not be assumed to be direct replacements for PCA3.

The 2023 AUA/SUO early detection guideline emphasizes that repeat-biopsy decisions should not use a PSA threshold alone. MRI and selective secondary biomarkers can help when their results would influence whether biopsy proceeds.

Accuracy and Important Limitations

PCA3 offered greater prostate-cancer specificity than PSA, but its diagnostic performance was only moderate. A 2025 systematic review of recent urinary prostate biomarkers concluded that the PROGENSA PCA3 score had moderate sensitivity and specificity and performed less impressively than some newer non-DRE urine tests for detecting clinically significant cancer.

Important limitations include:

• It is not a diagnostic test by itself. A biopsy is required to confirm prostate cancer.
• It does not reliably determine aggressiveness. A higher score generally raises the chance of a positive biopsy but does not map cleanly to Grade Group or stage.
• Collection is procedure-dependent. Historical PCA3 testing required a properly performed DRE and first-catch urine collection.
• Cutoffs vary in the literature. Research thresholds of 20, 25, 30, and 35 can create confusion if the specific assay is not identified.
• Predictive values depend on pretest risk. The same score can mean something different in a low-risk man than in someone with strong family history, a suspicious MRI, or persistent PSA elevation.
• A negative result can miss cancer. Even at a useful cutoff, sensitivity is not 100%.
• Current availability has changed. The historical FDA-approved PROGENSA PCA3 device had its U.S. PMA withdrawn in 2023.

Withdrawal of a device approval record should not be interpreted as proof that the underlying PCA3 biology was disproven. Products can leave the market for commercial, manufacturing, or strategic reasons. However, the withdrawal does mean patients and clinicians should not discuss PROGENSA as if it were an unchanged, routinely available U.S. assay in 2026.

PCA3 also has an “era” limitation. It was developed before prostate MRI became as central to biopsy pathways as it is today. Newer studies increasingly evaluate biomarkers in combination with MRI or focus specifically on Grade Group 2 or higher cancer rather than on any positive biopsy. That shift changes what clinicians expect from a useful secondary test.

Another limitation is that a biomarker can change the probability of cancer without answering whether finding that cancer would improve a person’s health. Age, life expectancy, competing medical conditions, and willingness to undergo treatment all affect the value of pursuing biopsy. In a healthy younger man with a suspicious MRI, clinicians may accept a lower threshold for biopsy. In an older person with serious competing illness, a modestly elevated molecular risk may not lead to an invasive procedure if the result would not change management. PCA3 therefore belongs inside shared decision-making rather than outside it.

Where PCA3 Fits in Prostate Testing Today

PCA3 remains scientifically important even though the original PROGENSA product is no longer active in the United States. The gene is still used in prostate-cancer research and can appear as a component of newer urine-based molecular strategies.

Modern pre-biopsy testing focuses increasingly on identifying clinically significant prostate cancer, usually Grade Group 2 or higher, while reducing biopsies likely to show benign tissue or Grade Group 1 disease. Recent reviews describe several available or emerging blood and urine tests, including PHI, 4Kscore, ExoDx, SelectMDx, and other multi-marker approaches.

The SelectMDx urine test, for example, uses a different gene-expression model. ExoDx uses urinary exosome RNA and does not require DRE. Blood tests such as PHI and 4Kscore avoid urine collection entirely. None of these choices is automatically best for every patient.

MRI has also changed the decision pathway. A high-quality multiparametric MRI can identify lesions for targeted biopsy and provide an anatomic risk estimate. Biomarkers can sometimes help before MRI, after MRI, or when imaging and clinical factors leave uncertainty. The optimal sequence depends on local practice, cost, availability, previous testing, and how the result will influence the decision.

One practical caution is to avoid stacking multiple biomarkers without a clear plan. If PSA, MRI, a blood risk score, and a urine score all disagree, adding more tests may increase confusion rather than clarity. The purpose of secondary testing is to move an uncertain decision toward a safer choice, not to collect as many scores as possible.

For people reviewing older medical records, a historical PCA3 result can still provide context. It should be interpreted according to the assay and standards used at the time, then integrated with current PSA, MRI, health status, and any subsequent biopsy results.

It is also useful to separate test availability from biomarker relevance. PCA3 can remain a scientifically meaningful gene even when a specific commercial assay is withdrawn. Laboratories or newer products may use PCA3 differently, with different companion markers and algorithms. That is why copying the old PROGENSA cutoff onto a modern multi-gene report can produce a serious interpretation error.

Next Steps After a PCA3 Result

If you have an older PROGENSA PCA3 report, first confirm the score, collection date, and whether it was obtained after the required DRE. A result below 25 historically reduced the likelihood of a positive repeat biopsy; a result of 25 or higher increased it. Scores near 25 deserved extra caution because small analytical differences could change the positive/negative category.

If you are being offered PCA3 testing now, ask exactly what product or laboratory-developed assay is being used. Because the FDA PMA for PROGENSA was withdrawn in 2023, the name “PCA3 test” alone is not enough to determine the correct collection method, cutoff, or evidence base.

For a low-risk result, the follow-up question is whether biopsy can be safely deferred. The answer may depend on MRI findings, PSA density, prior biopsy quality, age, family history, and how PSA changes over time. Deferring biopsy should come with a specific monitoring plan rather than an open-ended assumption that cancer has been excluded.

For a high-risk result, the clinician usually considers whether MRI or biopsy is appropriate. A high PCA3 score does not justify treatment without tissue confirmation. If biopsy is performed, the pathology result—not the urine score—determines whether cancer is present and how it is graded.

Useful questions for a urology visit include:

• Which PCA3 assay was used, and is it the historical PROGENSA method or another test?
• What cutoff applies to this exact assay?
• Was the urine sample collected using the required DRE protocol?
• How do my PSA trend, PSA density, MRI findings, and prior biopsy affect the meaning of the score?
• If we do not biopsy now, what is the follow-up schedule and what findings would trigger biopsy later?

A PCA3 result can refine risk, but the safest decision comes from combining molecular information with current imaging, clinical risk, and a clear plan for follow-up.

References

• The impact of urine biomarkers for prostate cancer detection-A systematic state of the art review 2025 (Systematic Review)
• Serum and Urine Biomarkers for Prostate Cancer: A Mini Review 2025 (Review)
• Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer 2025 (Review)
• Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy 2023 (Guideline)
• Premarket Approval (PMA) 2026
• PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study 2013

Disclaimer

This article provides general information about PCA3 testing and does not replace individualized prostate-cancer evaluation. PCA3 results cannot diagnose, grade, or stage prostate cancer and must be interpreted with PSA, MRI, examination findings, prior biopsy results, and other risk factors. Because the historical PROGENSA PCA3 PMA was withdrawn in 2023, confirm the exact current assay and its instructions with the ordering clinician or laboratory.